Evidence map›Paper›PMID 27599850›Full record

ReviewTrends in cell biology2016

Applications of CRISPR Genome Engineering in Cell Biology.

Fangyuan Wang, Lei S Qi

Abstract readReview
In one paragraph

Review in Trends in cell biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed.

  1. Cell lineage tracing: Methods, applications, and challenges.Quantitative biology (Beijing, China) · 2025
    Review
  2. Review
  3. CRISPR/Cas9: a powerful tool in colorectal cancer research.Journal of experimental & clinical cancer research : CR · 2023
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Nucleic Acid Delivery from Granular Hydrogels.Advanced healthcare materials · 2022
    Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. The evolving CRISPR technology.Protein & cell · 2019
    Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Fangyuan WangSino-U.S. Center of Synthetic Biology, Shanghai Institute of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Lei S QiDepartment of Bioengineering, Stanford University, Stanford, CA 94305, USA; Department of Chemical and Systems Biology, Stanford University, Stanford, CA 94305, USA; ChEM-H, Stanford University, Stanford, CA 94305, USA. Electronic address: stanley.qi@stanford.edu.

Funding

A novel RNA-guided platform for sequence-specific cell reprogrammingDP5OD017887 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI QI, LEI STANLEY · 2013 to 2017
$2.0M
NIH HHS DP5 OD017887
6 · The paper itself

Abstract

Recent advances in genome engineering are starting a revolution in biological research and translational applications. The clustered regularly interspaced short palindromic repeats (CRISPR)-associated RNA-guided endonuclease CRISPR associated protein 9 (Cas9) and its variants enable diverse manipulations of genome function. In this review, we describe the development of Cas9 tools for a variety of applications in cell biology research, including the study of functional genomics, the creation of transgenic animal models, and genomic imaging. Novel genome engineering methods offer a new avenue to understand the causality between the genome and phenotype, thus promising a fuller understanding of cell biology.

Indexed as

Cell BiologyGenomeAnimalsCRISPR-Cas SystemsEpigenesis, GeneticGenetic EngineeringHumansRNA, Guide, CRISPR-Cas SystemsRNA, Guide, CRISPR-Cas Systemscell biologyCRISPR/Cas9CRISPRi/agene editinggene regulation

Identifiers

PMID27599850
PMCPMC5077632

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.